Skip to main content
Clinical Trials/CTRI/2023/07/055618
CTRI/2023/07/055618Not yet recruitingPhase 3

A Comparative Study To Evaluate The Efficacy Of Shuntividangadi Grita Nasya And Vidanga Taila Nasya In The Kaphaja Shirashoola With Special Referance to Maxillary Sinusitis.

Dr K Raksha J Udupa1 site in 1 country40 target enrollmentStarted: July 28, 2023Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
X-ray water’s view

Study Overview

Brief Summary

NEED FOR THE STUDY

Shiras occupying the prime place in human body has to beprotected by all means, as it one among *dasha pranayatanas.*Kaphaja shira shoola is oneamong types of shirarogas explained Acharya Sushrutha,characterized by phlegm in throat and face, heaviness in the head, oedema offace and eyelids.

Most of the clinical features are correlated with signs andsymptoms of maxillary sinusitis, this condition is becoming more significant inpopulation because of few nidanas such as Rajo-Dhoomasevana(atmosphericpollutants), Purovatasevana(exposure to wind currents), ambukrida (swimming)sheeta, madhura, guru snigdha ahara.

Kaphaja shira shoola featuresinclude mild/modest headache and heaviness of head. The headache persiststhroughout the day, and it may increase at night. This condition is commonly associated with nasal discharge,nasal obstruction, and postnasal discharge.Sinusitis affects the mucosa of nose and para nasal sinusaffecting approximately 15% population in India. It is seen that increased airpollution and exposure to cold and flu have caused an increase in thiscondition.Over 85% of people with cold inflamed sinus. Theseinflammations are typically brief & mild. Only between 0.5% and 5% peoplewith cold develop true sinusitis. Maxillary sinusitis are most common sites.Conservative treatment is indicated for Maxillary Sinusitislike Antibiotics, nasal decongestant drops, steam inhalation, analgesics.

In this scenario, where there is no effective cure forSinusitis in modern medicine, Ayurvedic line of management may be beneficial.Acharya Sushrutha has mentioned that the patient suffering fromkaphaja shira shoola gets relived from the symptoms by kaphahara,teekshna nasya. Nasya karma is easy to administer, cost effective, easilyacceptable by patients and can be done at OPD level. Considering the abovefactors this study was taken up.So Shuntividangadi Grita is used forNasya as drugs used in this formulation has Kaphahara property.

HYPOTHESIS:

1.   1. Null hypothesis H0 – shuntividangadi grita Nasya and vidangataila Nasya is not having any effect on kaphaja shirashoola.

2.Alternative hypothesis H1- shuntividangadi griita nasya is having better effect than vidanga taila Nasyain reducing kaphaja shirashoola.

3. 3. Alternate hypothesis H2: vidangataila nasya is having better effect than shunti vidanga grita Nasyain reducing kaphaja shirashoola.

4. Alternate hypothesis H3: shuntividangadigrita nasya is having equal effect in reducing kaphaja shirashoolacompared to vidanga taila nasya.

Study Design

Study Type
Interventional
Allocation
Coin toss, Lottery, toss of dice, shuffling cards etc
Masking
Open Label

Eligibility Criteria

Ages
18.00 Year(s) to 60.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •1.Kaphaja sirashoola Lakshana are observed and included.
  • •2.Patient belonging to the age group of 18-60 years.
  • •3.Patient are selected irrespective of sex, occupation religion, socio-economic status etc.
  • •4.Those who are eligible for Nasya karma.
  • •5.Patient with X-ray showing haziness in Maxillary Sinus are included.

Exclusion Criteria

  • •1.Patients associated with other systemic illness.
  • •2..Patients with complication of maxillary sinusitis.
  • •3.Patients suffering from headache which is caused due to migrane/tension headach.
  • •4.Patients with contraindications of Nasyakarma were excluded.

Outcomes

Primary Outcomes

X-ray water’s view

Time Frame: 58 days

Secondary Outcomes

  • 1.Headache(2.Heaviness of head)

Investigators

Sponsor
Dr K Raksha J Udupa
Sponsor Class
Other [self]

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
A Community Trial to Determine Whether 'Safe Storage' Reduces Pesticide Self-poisoning in Rural AsiaPesticide Poisoning
NCT01146496University of Edinburgh223,861
Completed
Phase 1
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453Healthy
NCT02052687Novartis Pharmaceuticals41
Not yet recruiting
Phase 4
The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with MethotrexateRheumatoid Arthritis (RA)Methotrexate Induced NephrotoxicityMethotrexate Adverse Reaction
NCT06641128Tanta University44
Active, not recruiting
Phase 1
Estudio pivotal para determinar la eficacia y seguridad de AP23573 administrado como tratamiento de mantenimiento a pacientes con sarcoma metastásico óseo o de partes blandas.Patients who have benefited from cytotoxic chemotherapy. Patients will have either metastatic soft-tissue or bone sarcoma, with histological category (soft-tissue or bone) as one of the baseline stratification factors. Impotantly, in this trial, bone sarcoma patients must have visceral metastatic disease (e.g., metastatic to lung or liver), or have achieved response of visceral metasrasis.MedDRA version: 9.1Level: LLTClassification code 10006008Term: Bone sarcoma NOSMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomas
EUCTR2007-003462-18-ESARIAD Pharmaceuticals, Inc.675
Completed
Phase 1
Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 VaccinesInfluenza
NCT01086566National Institute of Allergy and Infectious Diseases (NIAID)95